

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10762210	
	Filing Date		2004-01-20	
	First Named Inventor	Ronald J. Berenson		
	Art Unit	1651		
	Examiner Name	Taeyoon Kim		
Attorney Docket Number		980034.417C5		

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button.

Add

NON-PATENT LITERATURE DOCUMENTS			Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10762210
Filing Date	2004-01-20
First Named Inventor	Ronald J. Berenson
Art Unit	1651
Examiner Name	Taeyoon Kim
Attorney Docket Number	980034.417C5

1	ANONYMOUS, "Xcyte Therapies Presents Clinical Results From Clinical Trials In Chronic Lymphocytic Leukemia And Multiple Myeloma At The American Society of Hematology (ASH)," Biospace Beat, URL= http://www.biospace.com/news_story.aspx?StoryID=14618620&full=1 >, download date September 25, 2008.	<input type="checkbox"/>
2	BONYHADI et al., "Expansion of Antigen-Specific CTL Using CD3/CD28 Paramagnetic Microbeads (Xcellerate™ Beads) for Adoptive Cellular Therapy of Melanoma," Blood, 98(11):32B-33B, November 16, 2001.	<input type="checkbox"/>
3	DROBYSKI et al., "Ex Vivo Anti-CD3 Antibody-Activated Donor T Cells Have a Reduced Ability to Cause Lethal Murine Graft-Versus-Host Disease but Retain Their Ability to Facilitate Allogeneic Engraftment," J. Immunol., 161(5):2610-2619, September 1, 1998.	<input type="checkbox"/>
4	JONES et al., "Post-Hematopoietic Cell Transplantation Control of Graft-versus-Host Disease by Donor CD4+25+ T Cells to Allow an Effective Graft-versus-Leukemia Response," Biol. of Blood and Marrow Transplantation, 9:243-256, 2003.	<input type="checkbox"/>
5	MARKTEL et al., "Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation," Blood, 101(4):1290-1298, February 15, 2003.	<input type="checkbox"/>
6	MULLER et al., "Induction of Apoptosis and Anergy in Resting Human T-Lymphocytes After CD3-Triggering and Its Modulation by CD28 and Cytokines," European J. Cancer, 31(1003):S34, October 1995.	<input type="checkbox"/>
7	MULLER et al., "Reduction of CD3-Mediated Apoptosis in Human T Cells By CD28-Costimulation: Possible Mechanisms," European J. of Cancer, 33:S35, June 1997.	<input type="checkbox"/>
8	NAPOLIS et al., "Mesenchymal Stem Cells Can Reduce Conditioning Requirements For Allogeneic Engraftment," Am. J. Transplantation, 4(s8):470, March 2004.	<input type="checkbox"/>
9	PARMAR et al., "Ex vivo expanded umbilical cord blood T cells maintain naive phenotype and TCR diversity," Cytotherapy, 8(2):149-157, 2006.	<input type="checkbox"/>
10	PORTER et al., "Graft-Versus-Tumor Induction With Donor Leukocyte Infusions as Primary Therapy for Patients With Malignancies," J. Clin. Oncol., 17(4):1234-1243, April 1999.	<input type="checkbox"/>
11	PORTER et al., "A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation," Blood, 107:1325-1331, November 3, 2005.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10762210
Filing Date	2004-01-20
First Named Inventor	Ronald J. Berenson
Art Unit	1651
Examiner Name	Taeyoon Kim
Attorney Docket Number	980034.417C5

12	RAPOPORT et al., "Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells," Bone Marrow Transplantation, 33:53-60, 2004.	<input type="checkbox"/>
13	RAPOPORT et al., "Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer," Nature Medicine, 11(11):1230-1237, November 2005.	<input type="checkbox"/>
14	RETTIG et al., "Kinetics of In Vivo Elimination of Suicide Gene-Expressing T Cells Affects Engraftment, Graft-versus-Host Disease, and Graft-versus-Leukemia after Allogeneic Bone Marrow Transplantation," J. Immunol., 173:3620-3630, 2004.	<input type="checkbox"/>
15	RETTIG et al., "Comparison of the Proliferative Kinetics, GVHD Potential and GCV Sensitivity of Naive and Transduced and Selected Murine T Cells after Allogeneic BMT," Blood (ASH Annual Meeting Abstracts), 106: Abstract 5257, 2005.	<input type="checkbox"/>
16	SHIBUYA et al., "Anti-CD3/Anti-CD28 Bead Stimulation Overcomes CD3 Unresponsiveness in Patients With Head and Neck Squamous Cell Carcinoma," Arch. Otolaryngol. Head Neck Surg., 126:473-479, 2000	<input type="checkbox"/>
17	SIEGEL et al., "A Phase III Study of Xcellerated T Cells™ after Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma," Blood (ASH Annual Meeting Abstracts), 104: Abstract 925, 2004.	<input type="checkbox"/>
18	SLAVIN et al., "Immunotherapy of cancer with alloreactive lymphocytes," Lancet Oncol., 2:491-498, August 2001.	<input type="checkbox"/>
19	STEFANSKI et al., "Transduction and Expansion of T Lymphocytes Genetically Engineered To Target the CD19 Antigen for the Treatment of CLL Using Xcyte™ Dynabeads®," Molecular Therapy, 11(Supp. 1):S274, May 2005.	<input type="checkbox"/>
20	TANG et al., "In Vitro-expanded Antigen-specific Regulatory T Cells Suppress Autoimmune Diabetes," J. Exp. Med., 199(11):1455-1465, June 7, 2004.	<input type="checkbox"/>
21	TAYLOR et al., "The infusion of ex vivo activated and expanded CD4+CD25+ immune regulatory cells inhibits graft-versus-host disease lethality," Blood, 99:3493-3499, 2002.	<input type="checkbox"/>
22	TAYLOR et al., "L-Selectinhi but not the L-selectinlo CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection," Blood, 104:3804-3812, August 3, 2004.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10762210
Filing Date	2004-01-20
First Named Inventor	Ronald J. Berenson
Art Unit	1651
Examiner Name	Taeyoon Kim
Attorney Docket Number	980034.417C5

23	THOMPSON et al., "A Phase I Trial of CD3/CD28-activated T Cells (Xcellerated T Cells) and Interleukin-2 in Patients with Metastatic Renal Cell Carcinoma," Clin. Cancer Res., 9:3562-3570, September 1, 2003.	<input type="checkbox"/>
24	THORNTON et al., "Activation requirements for the induction of CD4+CD25+ T cell suppressor function," European J. Immunol., 34:366-376, 2004.	<input type="checkbox"/>
25	TRENADO et al., "Ex Vivo-Expanded CD4+ CD25+ Immunoregulatory T Cells Prevent Graft-versus-Host-Disease by Inhibiting Activation/Differentiation of Pathogenic T Cells," J. Immunol., 176:1266-1273, 2006.	<input type="checkbox"/>
26	VAN RIJN et al., "Quantitative Assessment of Human T Lymphocytes in RAG2-/- mice: The Impact of Ex Vivo Manipulation on In Vivo Functionality," Exper. Hematol., 35:117-127, 2007.	<input type="checkbox"/>
27	VIJ et al., "A Phase I/II Study of Xcellerated T Cells™ after Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma," Blood (ASH Annual Meeting Abstracts), 102(11): Abstract 139, 2003.	<input type="checkbox"/>
28	VIJ et al., "A Randomized Phase II Study of Xcellerated T Cells™ with or without Prior Fludarabine Therapy in Patients with Multiple Myeloma (MM)," ASCO Annual Meeting Proceedings, 23(16S):2582, June 1, 2005.	<input type="checkbox"/>
29	WEI et al., "Mapping the sensitivity of T cells with an optical trap: Polarity and minimal number of receptors for Ca2+ signaling," Proc. Natl. Acad. Sci. USA, 96:8471-8476, July 1999.	<input type="checkbox"/>
30	XIA et al., "Targeting Acute Allograft Rejection by Immunotherapy With Ex Vivo-Expanded Natural CD4+CD25+ Regulatory T Cells," Transplantation, 82(12):1749-1755, December 27, 2006.	<input type="checkbox"/>
31	ZAPATA-SIRVENT et al., "Temporal analysis of human leucocyte surface antigen expression and neutrophil respiratory burst activity after thermal injury," Burns, 19(1):5-11, 1993.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10762210
Filing Date	2004-01-20
First Named Inventor	Ronald J. Berenson
Art Unit	1651
Examiner Name	Taeyoon Kim
Attorney Docket Number	980034.417C5

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.